{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:25:14Z","timestamp":1788279914980,"version":"build-2803163510"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca plc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.diabres.2022.109781","type":"journal-article","created":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T02:05:13Z","timestamp":1644890713000},"page":"109781","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Metabolic changes induced by dapagliflozin, an SGLT2 inhibitor, in Japanese patients with type 2 diabetes treated by oral anti-diabetic agents: A randomized, clinical trial"],"prefix":"10.1016","volume":"186","author":[{"given":"Kayo","family":"Horibe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsutaro","family":"Morino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itsuko","family":"Miyazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiko","family":"Tanaka-Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsuko","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shogo","family":"Ida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Yanagimachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1757-5313","authenticated-orcid":false,"given":"Ryuta","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Murata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuyuki","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisatomi","family":"Arima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiro","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Ugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Maegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.diabres.2022.109781_b0005","doi-asserted-by":"crossref","first-page":"e009417","DOI":"10.1136\/bmjopen-2015-009417","article-title":"SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis","volume":"6","author":"Shyangdan","year":"2016","journal-title":"BMJ Open"},{"issue":"11","key":"10.1016\/j.diabres.2022.109781_b0010","doi-asserted-by":"crossref","first-page":"e0166125","DOI":"10.1371\/journal.pone.0166125","article-title":"Benefits and harms of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"11","author":"Storgaard","year":"2016","journal-title":"PLoS ONE"},{"issue":"4","key":"10.1016\/j.diabres.2022.109781_b0015","doi-asserted-by":"crossref","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","article-title":"Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis","volume":"159","author":"Vasilakou","year":"2013","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.diabres.2022.109781_b0020","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1210\/jc.2011-2260","article-title":"Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin","volume":"97","author":"Bolinder","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"issue":"5","key":"10.1016\/j.diabres.2022.109781_b0025","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.2337\/db15-1356","article-title":"Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes","volume":"65","author":"Ferrannini","year":"2016","journal-title":"Diabetes"},{"issue":"11","key":"10.1016\/j.diabres.2022.109781_b0030","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.2337\/dc15-2688","article-title":"Dapagliflozin enhances fat oxidation and ketone production in patients with type 2 diabetes","volume":"39","author":"Daniele","year":"2016","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.diabres.2022.109781_b0040","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3390\/metabo11020087","article-title":"The effects of SGLT2 inhibitors on lipid metabolism","volume":"11","author":"Szekeres","year":"2021","journal-title":"Metabolites"},{"key":"10.1016\/j.diabres.2022.109781_b0045","first-page":"299","article-title":"Regulation of in vivo ketogenesis: role of free fatty acids and control by epinephrine, thyroid hormones, insulin and glucagon","volume":"22","author":"Beylot","year":"1996","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.diabres.2022.109781_b0050","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.cmet.2007.05.003","article-title":"Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21","volume":"5","author":"Inagaki","year":"2007","journal-title":"Cell Metab"},{"issue":"8","key":"10.1016\/j.diabres.2022.109781_b0055","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.metabol.2016.01.001","article-title":"Non-alcoholic fatty liver disease and diabetes","volume":"65","author":"Hazlehurst","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.diabres.2022.109781_b0060","doi-asserted-by":"crossref","first-page":"222","DOI":"10.18433\/jpps29831","article-title":"Effects of canagliflozin on fatty liver indexes in patients with type 2 diabetes: a meta-analysis of randomized controlled trials","volume":"21","author":"Li","year":"2018","journal-title":"J Pharm Pharm Sci"},{"key":"10.1016\/j.diabres.2022.109781_b0065","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.diabres.2019.01.029","article-title":"Effect of canagliflozin on the overall clinical state including insulin resistance in Japanese patients with type 2 diabetes mellitus","volume":"149","author":"Koike","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"10.1016\/j.diabres.2022.109781_b0070","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/jdi.12851","article-title":"Sodium-glucose cotransporter 2 inhibitor-induced changes in body composition and simultaneous changes in metabolic profile: 52-week prospective LIGHT (Luseogliflozin: the Components of Weight Loss in Japanese Patients with Type 2 Diabetes Mellitus) Study","volume":"10","author":"Sasaki","year":"2019","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.diabres.2022.109781_b0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/6470137","article-title":"Effect of tofogliflozin on body composition and glycemic control in japanese subjects with type 2 diabetes mellitus","volume":"2018","author":"Kamei","year":"2018","journal-title":"J Diabetes Res."},{"issue":"6","key":"10.1016\/j.diabres.2022.109781_b0080","doi-asserted-by":"crossref","first-page":"467","DOI":"10.5551\/jat.40873","article-title":"Dapagliflozin reduces fat mass without affecting muscle mass in type 2 diabetes","volume":"25","author":"Sugiyama","year":"2018","journal-title":"J Atheroscler Thromb"},{"issue":"4","key":"10.1016\/j.diabres.2022.109781_b0085","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1111\/jdi.12985","article-title":"Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: a randomized clinical trial","volume":"10","author":"Inoue","year":"2019","journal-title":"J Diabetes Investig"},{"issue":"6","key":"10.1016\/j.diabres.2022.109781_b0090","doi-asserted-by":"crossref","first-page":"749","DOI":"10.17219\/acem\/70796","article-title":"The influence of a 3-week body mass reduction program on the metabolic parameters and free amino acid profiles in adult Polish people with obesity","volume":"27","author":"Moszak","year":"2018","journal-title":"Adv Clin Exp Med"},{"key":"10.1016\/j.diabres.2022.109781_b0095","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2021.640621","article-title":"A muscle-centric perspective on intermittent fasting: a suboptimal dietary strategy for supporting muscle protein remodeling and muscle mass?","volume":"8","author":"Williamson","year":"2021","journal-title":"Front Nutr"},{"issue":"10","key":"10.1016\/j.diabres.2022.109781_b0100","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1161\/CIRCULATIONAHA.117.029166","article-title":"Effect of Empagliflozin on the Metabolic Signature of Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease","volume":"136","author":"Kappel","year":"2017","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.diabres.2022.109781_b0105","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s10334-012-0310-2","article-title":"Hepatic lipid composition differs between ob\/ob and ob\/+ control mice as determined by using in vivo localized proton magnetic resonance spectroscopy","volume":"25","author":"Ye","year":"2012","journal-title":"MAGMA"},{"issue":"2","key":"10.1016\/j.diabres.2022.109781_b0110","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/1522-2594(200008)44:2<201::AID-MRM6>3.0.CO;2-5","article-title":"High-resolution (1)H and (1)H-(13)C magic angle spinning NMR spectroscopy of rat liver","volume":"44","author":"Bollard","year":"2000","journal-title":"Magn Reson Med"},{"issue":"2","key":"10.1016\/j.diabres.2022.109781_b0115","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/dom.12189","article-title":"Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin","volume":"16","author":"Bolinder","year":"2014","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"10.1016\/j.diabres.2022.109781_b0120","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc17-0518","article-title":"Comparison of ipragliflozin and pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes: a randomized, 24-week, open-label, active-controlled trial","volume":"40","author":"Ito","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2022.109781_b0125","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.2337\/dbi18-0024","article-title":"Targeting metabolism, insulin resistance, and diabetes to treat nonalcoholic steatohepatitis","volume":"67","author":"Finck","year":"2018","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.diabres.2022.109781_b0130","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/jmri.22580","article-title":"Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy","volume":"34","author":"Reeder","year":"2011","journal-title":"J Magn Reson Imaging"},{"issue":"2","key":"10.1016\/j.diabres.2022.109781_b0135","doi-asserted-by":"crossref","first-page":"E462","DOI":"10.1152\/ajpendo.00064.2004","article-title":"Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population","volume":"288","author":"Szczepaniak","year":"2005","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.diabres.2022.109781_b0140","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.2337\/db09-0916","article-title":"Magnetic resonance spectroscopy studies of human metabolism","volume":"60","author":"Befroy","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.diabres.2022.109781_b0145","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT Trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2022.109781_b0150","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1038\/oby.2012.168","article-title":"A single MRI slice does not accurately predict visceral and subcutaneous adipose tissue changes during weight loss","volume":"20","author":"Shen","year":"2012","journal-title":"Obesity (Silver Spring)"},{"issue":"4","key":"10.1016\/j.diabres.2022.109781_b0155","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1080\/00325481.2016.1169894","article-title":"Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks","volume":"128","author":"Blonde","year":"2016","journal-title":"Postgrad Med"},{"issue":"1","key":"10.1016\/j.diabres.2022.109781_b0160","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1152\/jappl.1968.25.1.52","article-title":"Influence of dietary deprivations on plasma concentration of free amino acids of man","volume":"25","author":"Adibi","year":"1968","journal-title":"J Appl Physiol"},{"key":"10.1016\/j.diabres.2022.109781_b0165","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1042\/bj1020942","article-title":"The rate of gluconeogenesis from various precursors in the perfused rat liver","volume":"102","author":"Ross","year":"1967","journal-title":"Biochem J"},{"issue":"2","key":"10.1016\/j.diabres.2022.109781_b0170","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1172\/JCI70704","article-title":"Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production","volume":"124","author":"Merovci","year":"2014","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.diabres.2022.109781_b0175","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1007\/BF00282518","article-title":"Effect of poor diabetic control and obesity on whole body protein metabolism in man","volume":"25","author":"Nair","year":"1983","journal-title":"Diabetologia"},{"issue":"3","key":"10.1016\/j.diabres.2022.109781_b0180","doi-asserted-by":"crossref","first-page":"e59443","DOI":"10.1371\/journal.pone.0059443","article-title":"Leucine and protein metabolism in obese Zucker rats","volume":"8","author":"She","year":"2013","journal-title":"PLoS ONE"},{"issue":"15","key":"10.1016\/j.diabres.2022.109781_b0185","doi-asserted-by":"crossref","first-page":"11348","DOI":"10.1074\/jbc.M109.075184","article-title":"Adipose tissue branched chain amino acid (BCAA) metabolism modulates circulating BCAA levels","volume":"285","author":"Herman","year":"2010","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.diabres.2022.109781_b0190","doi-asserted-by":"crossref","first-page":"E1552","DOI":"10.1152\/ajpendo.00134.2007","article-title":"Obesity-related elevations in plasma leucine are associated with alterations in enzymes involved in branched-chain amino acid metabolism","volume":"293","author":"She","year":"2007","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.diabres.2022.109781_b0195","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1210\/clinem\/dgab086","article-title":"Effect of Dapagliflozin on urine metabolome in patients with type 2 diabetes","volume":"106","author":"Bletsa","year":"2021","journal-title":"J Clin Endocrinol Metab."}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822722005939?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822722005939?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:23:13Z","timestamp":1759173793000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822722005939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":38,"alternative-id":["S0168822722005939"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2022.109781","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolic changes induced by dapagliflozin, an SGLT2 inhibitor, in Japanese patients with type 2 diabetes treated by oral anti-diabetic agents: A randomized, clinical trial","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2022.109781","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109781"}}